A case of calcinosis universalis successfully treated with low-dose warfarin

Journal of Dermatology

Volumn 25, Issue 11, 1998, Pages 716-720

  Matsuoka, Yukari ^a,b   Miyajima, Susumu ^a   Okada, Natsuko ^a  

^a OSAKA KOSEI NENKIN HOSPITAL   (Japan)

^b OSAKA POLICE HOSPITAL   (Japan)

Author keywords

Calcinosis universalis; Dermatomyositis; Therapy; Vitamin K; Warfarin

Indexed keywords

4 CARBOXYGLUTAMIC ACID; CALCIUM BINDING PROTEIN; WARFARIN;

ADULT; ARTICLE; BLEEDING TENDENCY; CALCIFICATION; CALCINOSIS; CARBOXYLATION; CASE REPORT; DERMATOMYOSITIS; DOSE RESPONSE; HUMAN; KNEE FUNCTION; MALE; ORAL DRUG ADMINISTRATION; SUBCUTANEOUS NODULE;

EID: 0031701102     PISSN: 03852407     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1346-8138.1998.tb02490.x     Document Type: Article

References (13)

1. Boyd AS, Neider KH: Therapeutic options in dermatomyositis/polymyositis, Int J Dermatol, 33: 240-250, 1994.
2. Bassett CAL, Donath A, Macagno F, Preisig R, Fleisch H, Francis MD: Diphosphonates in the treatment of myositis ossificans, Lancet, 2: 845, 1969.
3. Nassim JR, Connolly CK: Treatment of calcinosis universalis with aluminium hydroxide, Arch Dis Child, 45: 118-121, 1970.
4. Skuterud E, Sydnes OA, Haavik TK: Calcinosis in dermatomyositis treated with probenecid, Scand J Rheumatol, 10: 92-94, 1981.
5. 2EDTA, Arthritis Rheum, 7: 259-271, 1964.
6. Dent CE, Stamp TCB: Treatment of calcinosis circumscripta with probenecid, Br Med J, 1: 216-218, 1972.
7. Taborn J, Bole GG, Thompson GR: Colchicine suppression of local and systemic inflammation due to calcinosis universalis in chronic dermatomyositis, Ann Intern Med, 89: 648-649, 1978.
8. Berger RG, Featherstone GL, Raasch RH, Mc Cartney WH, Hadler NM: Treatment of calcinosis universalis with low-dose warfarin, Am J Med, 83: 72-76, 1987.
9. Lassoued K, Saiag P, Anglade MC, Roujeau JC, Touraine RL: Failure of warfarin in treatment of calcinosis universalis, Am J Med, 84: 795-796, 1988.
10. Gallop PM, Lian JB, Hauschka PV: Carboxylated calcium binding proteins and vitamin K, N Engl J Med, 302: 1460-1466, 1980.
11. Fiore CE, Amburino C, Foti R, Grimaldi D: Reduced axial bone mineral content in patients taking an oral anticoagulant, Southern Med J, 83: 538-542, 1990.
12. Resch H, Pietschmann P, Krexner E, Willvonseder R: Decreased peripheral bone mineral content in patients under anticoagulant therapy with phenprocoumon, European Heart J, 12: 439-441, 1991.
13. Orimo H, Fujita T, Onomura T, Inoue T, Kushida K, Shiraki M: Clinical evaluation of Ea-0167 (Menatetrenone) in the treatment of osteoporosis, Clin Eval, 20: 45-100, 1992.